Pachyonychia Congenita Clinical Trials 2023

Pachyonychia Congenita Clinical Trials 2023

Pachyonychia Congenita research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in pachyonychia congenita clinical trials today.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to pachyonychia congenita

What are the top hospitals conducting pachyonychia congenita research?

In the realm of rare genetic disorders, pachyonychia congenita takes center stage, captivating the attention of leading hospitals across the United States. Stanford University in Palo Alto is one such institution dedicated to making strides in understanding and treating this condition. With three active clinical trials underway and an equal number completed to date, Stanford has been at the forefront since recording its first pachyonychia congenita trial in 2019. Not far behind are researchers at Yale University in New Haven, who are also conducting three ongoing clinical trials for this rare disorder while sharing a similar track record with their counterparts at Stanford.

Meanwhile, the Minnesota Clinical Study Center located in Fridley contributes significantly to advancing our knowledge of pachyonychia congenita as well. With three active trials currently in progress and an equal number completed throughout history since 2019's first recorded study on this topic, they continue to push boundaries alongside other esteemed institutions.

The University of Utah situated beautifully in Murray rises up as another noteworthy player within this domain by actively engaging with three ongoing pachyonychia congenita investigations while having accomplished three earlier studies too after initiating research efforts just two years ago.

Further expanding upon these remarkable medical advancements is Arizona Research Center based in Phoenix; here researchers have initiated two current exploratory endeavors related to pachyonychia congenita whilst holding commendable records of two previous studies conducted so far following their initial groundbreaking investigation commencing back into1993.These five prominent hospitals symbolize the collective pursuit for answers concerning a complex condition that affects individuals worldwide but remains relatively unknown among many people themselves. Through collaborative efforts and tireless dedication, these institutions pave a path towards better understanding and potential treatments for those affected by pachyonychia congenita

Which are the best cities for pachyonychia congenita clinical trials?

The best cities for pachyonychia congenita clinical trials are Palo Alto, California; New Haven, Connecticut; Fridley, Minnesota; Murray, Utah; and Portland, Oregon. These cities have a significant number of active trials focusing on treatments like Active, PTX-022, and Open label period. With ongoing research in these locations, individuals affected by pachyonychia congenita have access to cutting-edge clinical trials that aim to improve their quality of life and advance the understanding and treatment of this rare genetic disorder.

Which are the top treatments for pachyonychia congenita being explored in clinical trials?

Pachyonychia congenita, a rare genetic disorder, is currently the focus of clinical trials exploring potential treatments. One standout contender in these trials is PTX-022. This promising therapy has caught attention with its two active pachyonychia congenita trials and three all-time listings since 2019. As researchers delve deeper into understanding this condition, PTX-022 offers hope for those affected by pachyonychia congenita and may pave the way for future advancements in treatment options.

What are the most recent clinical trials for pachyonychia congenita?

Recent clinical trials have brought promising developments in the treatment of pachyonychia congenita, a rare genetic disorder. Of note is PTX-022, a Phase 3 trial that became available on 11/15/2022. This study aims to assess the efficacy and safety of this experimental therapy for individuals with pachyonychia congenita. Another significant trial is Active, also in Phase 3 and available since 11/29/2021. These trials represent essential steps towards identifying effective treatments for this debilitating condition. With ongoing research efforts like these, the future looks brighter for those affected by pachyonychia congenita

What pachyonychia congenita clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of pachyonychia congenita, a rare genetic disorder affecting the nails and skin. These efforts bring hope to patients seeking improved treatments. Notably, clinical trials investigating potential therapies for this condition have been concluded successfully. The completion of these trials marks an important milestone in advancing our understanding and treatment options for pachyonychia congenita.